Balyasny Asset Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Balyasny Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.5M	Buy	+1,448,000	New	+$37.2M	0.05%	441

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Balyasny Asset Management's DMRA Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 1,448,000 shares worth $37.5M. The stake represents 0.05% of the portfolio and ranks #441 among its holdings.

65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

Balyasny Asset Management held 1,448,000 shares of Damora Therapeutics, Inc. Ordinary Shares worth $37.5M as of Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares was a new Balyasny Asset Management position in Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares made up 0.05% of Balyasny Asset Management's portfolio in Q1 2026, its #441 holding.
65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.